following an abbreviated submission:
valganciclovir powder for 50mg/ml oral solution (Valcyte) is accepted for restricted use in NHS Scotland for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
Its use should be under the overall supervision of an expert ophthalmologist and a physician experienced in the management of HIV / AIDS patients. In patients for whom valganciclovir is an appropriate choice of therapy this is the only licensed formulation for those undergoing haemodialysis (creatinine clearance <10ml/minute). Otherwise its use should be restricted to patients unable to use the less costly solid oral dosage form.
Download detailed advice45KB (PDF)
- Medicine name:
- valganciclovir (Valcyte)
- SMC ID:
- Solid Organ Transplantation / AIDS
- Pharmaceutical company
- BNF chapter
- Submission type
- Date advice published
- 07 December 2009